This page contains a Flash digital edition of a book.
THE DANGERS OF COUNTERFEITING


dose (tablet, capsule or single-use vial cap) at any point in the supply chain, the forensic-level, nano-sized NanoCodes provide an additional level of authentication and comprehensive tracing information on each and every dose, including product information (strength, expiration date), manufacturing information (location, date, batch, lot number) and distribution information (country, distributor, wholesaler). Te process to decrypt the NanoCodes is non-destructive and can be completed within minutes, yielding the manufacturer with additional proof of authentication and a wealth of dose-level tracing data. NanoEncryption technology provides manufacturers with an unsurpassed ability to fight both counterfeiting and illegal diversion with a single on-dose weapon.


In order be proactive in the war against counterfeit and illegally diverted medications, manufacturers must take the fight to those who mean to harm them and their patients, by aggressively defending their IP and proactively monitoring the supply chain for intrusions of counterfeit or diverted product. One approach to supply chain auditing is data mining of manufacturer, wholesaler, distributor and retail pharmacy ordering patterns to look for discrepancies; NanoGuardian has launched a program directed specifically at the medication being dispensed to patients. NanoGuardian’s Closed-Loop Protection Program combines


www.worldipreview.com


the on-dose authentication and tracing benefits of NanoEncryption technology, statistical modelling and a proactive pharmacy auditing program to assist manufacturers in detecting counterfeit and illegally diverted products that have entered the supply chain. Tis reduces the risks to brands, companies and patients.


Counterfeit drugs impact the entire global supply chain, including manufacturers, governments and honest supply chain members. But none are affected more so than the innocent and unsuspecting patients who rely on these medicines for their health and well-being. Pharmaceutical manufacturers must continue their commitment and strengthen their focus on securing products and protecting patients by implementing comprehensive security strategies, including on-dose technologies that can have an immediate impact. By doing so, manufacturers can gain significant ground in the war against counterfeiting and illegal diversion, protect the reputation of their products, and ensure that patients continue to receive the medicinal benefits they expect and need.


Dean Hart joined NanoGuardian in February 2008 as executive vice president. He possesses more than 25 years of sales and marketing experience in the pharmaceutical marketplace. Most recently, he served as senior vice president of sales at Takeda Pharmaceuticals North America. Prior to joining Takeda, he served as national sales director for Eisai, Inc and began his pharmaceutical career at Bristol-Myers Squibb. Hart received a BSc degree in business management from Indiana University and a Masters of Business Administration degree from the Kellogg School of Management at Northwestern University.


Dean Hart is executive vice president at NanoGuardian. He can be contacted at: dhart@nanoink.net


World Intellectual Property Review November/December 2010 57


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108